BLTE Projected Dividend Yield
ADR/Belite Bio Inc ( NASDAQ : BLTE )Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. Co. is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as atrophic age-related macular degeneration (AMD), and autosomal recessive Stargardt disease type 1 (STGD) both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, LBS-008 as an oral daily treatment for STGD1 and Geographic Atrophy patients. 20 YEAR PERFORMANCE RESULTS |
BLTE Dividend History Detail BLTE Dividend News BLTE Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |